Role of PI3K-AKT-mTOR and Wnt signaling pathways in transition of G1-S phase of cell cycle in cancer cells

Frontiers in Oncology

Volumn 3 APR, Issue , 2013, Pages

  Vadlakonda, Lakshmipathi ^a   Pasupuleti, Mukesh ^b   Pallu, Reddanna ^c  

^a KAKATIYA UNIVERSITY   (India)

^b SRM INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

^c UNIVERSITY OF HYDERABAD   (India)

Author keywords

Autophagy; Cell cycle; G1 S; mTORC1; Wnt

Indexed keywords

BETA CATENIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; DISHEVELLED 1; DISHEVELLED 2; DISHEVELLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; INITIATION FACTOR 4E BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; RAPAMYCIN; RAS PROTEIN; S6 KINASE; TRANSCRIPTION FACTOR FOXO; TUBERIN;

ARTICLE; AUTOPHAGY; CANCER CELL; CELL CYCLE PROGRESSION; CELL METABOLISM; G1 PHASE CELL CYCLE CHECKPOINT; GLYCOLYSIS; HUMAN; NUCLEAR REPROGRAMMING; ONCOGENE; PENTOSE PHOSPHATE CYCLE; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY;

EID: 84886375160     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00085     Document Type: Article

References (112)

1. Abraham, R. T., and Wiederrecht, G. J. (1996). Immunopharmacology of rapamycin. Annu. Rev. Immunol. 14, 483-510.
2. Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R., Reese, C. B., et al. (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol. 7, 261-269.
3. Alvarez, B., Martinez, A. C., Burgering, B. M., and Carrera, A. C. (2001). Forkhead transcription factors contribute to execution of the mitotic programme in mammals. Nature 413, 744-747.
4. Aman, M. J., Lamkin, T. D., Okada, H., Kurosaki, T., and Ravichandran, K. S. (1998). The inositol phosphatase SHIP inhibits Akt/PKB activation in B cells. J. Biol. Chem. 273, 33922-33928.
5. Arima, Y., Hirota, T., Bronner, C., Mousli, M., Fujiwara, T., Niwa, S., et al. (2004). Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition. Genes Cells 9, 131-142.
6. Bellacosa, A., Testa, J. R., Staal, S. P., and Tsichlis, P. N. (1991). A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254, 274-277.
7. Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N., Nakano, K., Bartrons, R., et al. (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-120.
8. Bhagwat, S. V., and Crew, A. P. (2010). Novel inhibitors of mTORC1 and mTORC2. Curr. Opin. Investig. Drugs 11, 638-645.
9. Boidot, R., Vegran, F., Meulle, A., Le Breton, A., Dessy, C., Sonveaux, P., et al. (2012). Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. Cancer Res. 72, 939-948.
10. Brech, A., Ahlquist, T., Lothe, R. A., and Stenmark, H. (2009). Autophagy in tumour suppression and promotion. Mol. Oncol. 3, 366-375.
11. Breuleux, M., Klopfenstein, M., Stephan, C., Doughty, C. A., Barys, L., Maira, S. M., et al. (2009). Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol. Cancer Ther. 8, 742-753.
12. Castellvi, J., Garcia, A., Rojo, F., Ruiz-Marcellan, C., Gil, A., Baselga, J., et al. (2006). Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 107, 1801-1811.
13. Chen, C. C., Jeon, S. M., Bhaskar, P. T., Nogueira, V., Sundararajan, D., Tonic, I., et al. (2010). FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor. Dev. Cell 18, 592-604.
14. Chen, C. H., Shaikenov, T., Peterson, T. R., Aimbetov, R., Bissenbaev, A. K., Lee, S. W., et al. (2011). ER stress inhibits mTORC2 and Akt signaling through GSK-3beta-mediated phosphorylation of rictor. Sci. Signal. 4, ra10.
15. Chen, Y., and Klionsky, D. J. (2011). The regulation of autophagy-unanswered questions. J. Cell. Sci. 124, 161-170.
16. Coffer, P. J., and Woodgett, J. R. (1991). Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur. J. Biochem. 201, 475-481.
17. Corradetti, M. N., Inoki, K., Bardeesy, N., DePinho, R. A., and Guan, K. L. (2004). Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev. 18, 1533-1538.
18. Deretic, V. (2011). Autophagy in immunity and cell-autonomous defense against intracellular microbes. Immunol. Rev. 240, 92-104.
19. Dibble, C. C., Asara, J. M., and Manning, B. D. (2009). Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol. Cell. Biol. 29, 5657-5670.
20. Dong, L. Q., and Liu, F. (2005). PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle. Am. J. Physiol. Endocrinol. Metab. 289, E187-E196.
21. Dotto, G. P., Gilman, M. Z., Maruyama, M., and Weinberg, R. A. (1986). c-Myc and c-fos expression in differentiating mouse primary keratinocytes. EMBO J. 5, 2853-2857.
22. Downward, J. (1995). Signal transduction. A target for PI(3) kinase. Nature 376, 553-554.
23. Engelman, J. A., Luo, J., and Cantley, L. C. (2006). The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606-619.
24. Evangelisti, C., Ricci, F., Tazzari, P., Tabellini, G., Battistelli, M., Falcieri, E., et al. (2011). Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 25, 781-791.
25. Ferber, E. C., Peck, B., Delpuech, O., Bell, G. P., East, P., and Schulze, A. (2012). FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression. Cell Death Differ. 19, 968-979.
26. Fournier, M. V., Fata, J. E., Martin, K. J., Yaswen, P., and Bissell, M. J. (2009). Interaction of E-cadherin and PTEN regulates morphogenesis and growth arrest in human mammary epithelial cells. Cancer Res. 69, 4545-4552.
27. Gamper, C. J., and Powell, J. D. (2012). All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells. Front. Immunol. 3:312. doi:10.3389/fimmu.2012.00312
28. Gan, X. Q., Wang, J. Y., Xi, Y., Wu, Z. L., Li, Y. P., and Li, L. (2008). Nuclear Dvl, c-Jun, beta-catenin, and TCF form a complex leading to stabilization of beta-catenin-TCF interaction. J. Cell Biol. 180, 1087-1100.
29. Gao, C., Cao, W., Bao, L., Zuo, W., Xie, G., Cai, T., et al. (2010). Autophagy negatively regulates Wnt signalling by promoting Dishevelled degradation. Nat. Cell Biol. 12, 781-790.
30. Gao, C., and Chen, Y. G. (2010). Dishevelled: the hub of Wnt signaling. Cell. Signal. 22, 717-727.
31. Goncharova, E. A., Goncharov, D. A., Li, H., Pimtong, W., Lu, S., Khavin, I., et al. (2011). mTORC2 is required for proliferation and survival of TSC2-null cells. Mol. Cell. Biol. 31, 2484-2498.
32. Gottlieb, E. (2011). p53 guards the metabolic pathway less travelled. Nat. Cell Biol. 13, 195-197.
33. Guo, Z., Zhou, Y., Evers, B. M., and Wang, Q. (2012). Rictor regulates FBXW7-dependent c-Myc and cyclin E degradation in colorectal cancer cells. Biochem. Biophys. Res. Commun. 418, 426-432.
34. Guppy, A., Jamal-Hanjani, M., and Pickering, L. (2011). Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer. Future Oncol. 7, 727-736.
35. He, X., Wang, Y., Zhu, J., Orloff, M., and Eng, C. (2011). Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling. Cancer Lett. 301, 168-176.
36. Heallen, T., Zhang, M., Wang, J., Bonilla-Claudio, M., Klysik, E., Johnson, R. L., et al. (2011). Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 332, 458-461.
37. Hoogeboom, D., and Burgering, B. M. (2009). Should I stay or should I go: beta-catenin decides under stress. Biochim. Biophys. Acta 1796, 63-74.
38. Hoogeboom, D., Essers, M. A., Polderman, P. E., Voets, E., Smits, L. M., and Burgering, B. M. (2008). Interaction of FOXO with beta-catenin inhibits beta-catenin/T cell factor activity. J. Biol. Chem. 283, 9224-9230.
39. Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., et al. (2006). TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126, 955-968.
40. Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., et al. (2006). SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127, 125-137.
41. Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Ruegg, M. A., Hall, A., et al. (2004). Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6, 1122-1128.
42. Jiang, P., Du, W., Wang, X., Mancuso, A., Gao, X., Wu, M., et al. (2011). p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat. Cell Biol. 13, 310-316.
43. Julien, L. A., Carriere, A., Moreau, J., and Roux, P. P. (2010). mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol. Cell. Biol. 30, 908-921.
44. Kang, S., Chemaly, E. R., Hajjar, R. J., and Lebeche, D. (2011). Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways. J. Biol. Chem. 286, 18465-18473.
45. Katayama, K., Nakamura, A., Sugimoto, Y., Tsuruo, T., and Fujita, N. (2008). FOXO transcription factor-dependent p15(INK4b) and p19(INK4d) expression. Oncogene 27, 1677-1686.
46. Kim, J., Kundu, M., Viollet, B., and Guan, K. L. (2011). AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 13, 132-141.
47. Kim, J., Woo, A. J., Chu, J., Snow, J. W., Fujiwara, Y., Kim, C. G., et al. (2010). A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 143, 313-324.
48. Kim, J. W., Gao, P., Liu, Y. C., Semenza, G. L., and Dang, C. V. (2007). Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol. Cell. Biol. 27, 7381-7393.
49. Kim, L., and Kimmel, A. R. (2000). GSK3, a master switch regulating cell-fate specification and tumorigenesis. Curr. Opin. Genet. Dev. 10, 508-514.
50. Kode, A., Mosialou, I., Silva, B. C., Rached, M. T., Zhou, B., Wang, J., et al. (2012). FOXO1 orchestrates the bone-suppressing function of gut-derived serotonin. J. Clin. Invest. 122, 3490-3503.
51. Kumar, A., Lawrence, J. C. Jr., Jung, D. Y., Ko, H. J., Keller, S. R., Kim, J. K., et al. (2010). Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. Diabetes 59, 1397-1406.
52. Kwiatkowski, D. J., and Manning, B. D. (2005). Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum. Mol. Genet. 14, 251-258.
53. Land, H., Chen, A. C., Morgenstern, J. P., Parada, L. F., and Weinberg, R. A. (1986). Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts. Mol. Cell. Biol. 6, 1917-1925.
54. Laplante, M., and Sabatini, D. M. (2009). mTOR signaling at a glance. J. Cell. Sci. 122, 3589-3594.
55. Lee, J. H., Budanov, A. V., Park, E. J., Birse, R., Kim, T. E., Perkins, G. A., et al. (2010). Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science 327, 1223-1228.
56. Lemmon, M. A., and Schlessinger, J. (2010). Cell signaling by receptor tyrosine kinases. Cell 141, 1117-1134.
57. Leslie, N. R., Bennett, D., Lindsay, Y. E., Stewart, H., Gray, A., and Downes, C. P. (2003). Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J. 22, 5501-5510.
58. Lin, C. Y., Loven, J., Rahl, P. B., Paranal, R. M., Burge, C. B., Bradner, J. E., et al. (2012). Transcriptional amplification in tumor cells with elevated C-Myc. Cell 151, 56-67.
59. Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., et al. (2002). Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10, 457-468.
60. Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., and Pandolfi, P. P. (2005). Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121, 179-193.
61. Ma, X. M., and Blenis, J. (2009). Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 10, 307-318.
62. Maddocks, O. D., and Vousden, K. H. (2011). Metabolic regulation by p53. J. Mol. Med. 89, 237-245.
63. Mahajan, K., and Mahajan, N. P. (2012). PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics. J. Cell. Physiol. 227, 3178-3184.
64. Manning, B. D., and Cantley, L. C. (2007). AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274.
65. Markert, E. K., Levine, A. J., and Vazquez, A. (2012). Proliferation and tissue remodeling in cancer: the hallmarks revisited. Cell Death Dis. 3, e397.
66. Mendelsohn, J., and Baselga, J. (2003). Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21, 2787-2799.
67. Miron, M., Lasko, P., and Sonenberg, N. (2003). Signaling from Akt to FRAP/TOR targets both 4E-BP and S6K in Drosophila melanogaster. Mol. Cell. Biol. 23, 9117-9126.
68. Mita, M. M., Mita, A., and Rowinsky, E. K. (2003). The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol. Ther. 2, S169-S177.
69. Moore, P. A., Rosen, C. A., and Carter, K. C. (1996). Assignment of the human FKBP12-rapamycin-associated protein (FRAP) gene to chromosome 1p36 by fluorescence in situ hybridization. Genomics 33, 331-332.
70. Moore, S. F., Hunter, R. W., and Hers, I. (2011). mTORC2-mediated Akt Ser473 phosphorylation is not required for Akt1 activity in human platelets. J. Biol. Chem. 36, 374-387.
71. Nicholson, K. M., and Anderson, N. G. (2002). The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal. 14, 381-395.
72. Nusse, R. (2005). Wnt signaling in disease and in development. Cell Res. 15, 28-32.
73. Nyfeler, B., Bergman, P., Triantafellow, E., Wilson, C. J., Zhu, Y., Radetich, B., et al. (2011). Relieving autophagy and 4EBP1 from rapamycin resistance. Mol. Cell. Biol. 14, 2867-2876.
74. Pacheco-Pinedo, E. C., Durham, A. C., Stewart, K. M., Goss, A. M., Lu, M. M., Demayo, F. J., et al. (2011). Wnt/beta-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J. Clin. Invest. 121, 1935-1945.
75. Pearce, L. R., Komander, D., and Alessi, D. R. (2010). The nuts and bolts of AGC protein kinases. Nat. Rev. Mol. Cell Biol. 11, 9-22.
76. Polakis, P. (2012). Wnt signaling in cancer. Cold Spring Harb. Perspect. Biol. 4, a008052.
77. Riaz, A., Zeller, K. S., and Johansson, S. (2012). Receptor-specific mechanisms regulate phosphorylation of AKT at Ser473: role of RICTOR in beta1 integrin-mediated cell survival. PLoS ONE 7:e32081. doi:10.1371/journal.pone.0032081
78. Robey, R. B., and Hay, N. (2009). Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin. Cancer Biol. 19, 25-31.
79. Ronnebaum, S. M., and Patterson, C. (2012). The FoxO family in cardiac function and dysfunction. Annu. Rev. Physiol. 72, 81-94.
80. Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A. L., Nada, S., and Sabatini, D. M. (2010). Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141, 290-303.
81. Sarbassov, D. D., Ali, S. M., Kim, D. H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., et al. (2004). Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296-1302.
82. Sarbassov, D. D., Guertin, D. A., Ali, S. M., and Sabatini, D. M. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101.
83. Sato, J. D., Kawamoto, T., Le, A. D., Mendelsohn, J., Polikoff, J., and Sato, G. H. (1983). Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. 1, 511-529.
84. Schenone, S., Brullo, C., Musumeci, F., Radi, M., and Botta, M. (2011). ATP-competitive inhibitors of mTOR: an update. Curr. Med. Chem. 18, 2995-3014.
85. Schlessinger, J. (2000). Cell signaling by receptor tyrosine kinases. Cell 103, 211-225.
86. Shor, B., Gibbons, J. J., Abraham, R. T., and Yu, K. (2009). Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 8, 3831-3837.
87. Shoshan-Barmatz, V., De Pinto, V., Zweckstetter, M., Raviv, Z., Keinan, N., and Arbel, N. (2010). VDAC, a multi-functional mitochondrial protein regulating cell life and death. Mol. Aspects Med. 31, 227-285.
88. Soto Martinez, J. L., Cabrera Morales, C. M., Serrano Ortega, S., and Lopez-Nevot, M. A. (2005). Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15. Clin. Transl. Oncol. 7, 156-164.
89. Staal, S. P., Hartley, J. W., and Rowe, W. P. (1977). Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc. Natl. Acad. Sci. U.S.A. 74, 3065-3067.
90. Stein, J., Milewski, W. M., Hara, M., Steiner, D. F., and Dey, A. (2011). GSK-3 inactivation or depletion promotes beta-cell replication via down regulation of the CDK inhibitor, p27 (Kip1). Islets 3, 21-34.
91. Stipanuk, M. H. (2009). Macroautophagy and its role in nutrient homeostasis. Nutr. Rev. 67, 677-689.
92. Stott, F. J., Bates, S., James, M. C., McConnell, B. B., Starborg, M., Brookes, S., et al. (1998). The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17, 5001-5014.
93. Sun, A., Bagella, L., Tutton, S., Romano, G., and Giordano, A. (2007). From G0 to S phase: a view of the roles played by the retinoblastoma (Rb) family members in the Rb-E2F pathway. J. Cell. Biochem. 102, 1400-1404.
94. Swami, M. (2010). MYC matters. Nat. Rev. Cancer 10, 812.
95. Talchai, C., Xuan, S., Lin, H. V., Sussel, L., and Accili, D. (2012). Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. Cell 150, 1223-1234.
96. Thompson, D. M., and Gill, G. N. (1985). The EGF receptor: structure, regulation and potential role in malignancy. Cancer Surv. 4, 767-788.
97. Treins, C., Warne, P. H., Magnuson, M. A., Pende, M., and Downward, J. (2010). Rictor is a novel target of p70 S6 kinase-1. Oncogene 29, 1003-1016.
98. Veilleux, A., Houde, V. P., Bellmann, K., and Marette, A. (2010). Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes. Mol. Endocrinol. 24, 766-778.
99. Vincent, E. E., Elder, D. J., Thomas, E. C., Phillips, L., Morgan, C., Pawade, J., et al. (2011). Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer. Br. J. Cancer 104, 1755-1761.
100. Wang, H., Brown, J., Gu, Z., Garcia, C. A., Liang, R., Alard, P., et al. (2011). Convergence of the mammalian target of rapamycin complex 1-and glycogen synthase kinase 3-beta-signaling pathways regulates the innate inflammatory response. J. Immunol. 186, 5217-5226.
101. Wang, Z., Zhong, J., Inuzuka, H., Gao, D., Shaik, S., Sarkar, F. H., et al. (2012). An evolving role for DEPTOR in tumor development and progression. Neoplasia 14, 368-375.
102. Warburg, O. (1956). On the origin of cancer cells. Science 123, 309-314.
103. Weihl, C. C. (2011). Valosin containing protein associated fronto-temporal lobar degeneration: clinical presentation, pathologic features and pathogenesis. Curr. Alzheimer Res. 8, 252-260.
104. White, E., and Lowe, S. W. (2009). Eating to exit: autophagy-enabled senescence revealed. Genes Dev. 23, 784-787.
105. Wu, D., and Pan, W. (2010). GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem. Sci. 35, 161-168.
106. Wullschleger, S., Loewith, R., and Hall, M. N. (2006). TOR signaling in growth and metabolism. Cell 124, 471-484.
107. Xie, X., Zhang, D., Zhao, B., Lu, M. K., You, M., Condorelli, G., et al. (2011). IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 108, 6474-6479.
108. Yang, Z., and Klionsky, D. J. (2010). Eaten alive: a history of macroautophagy. Nat. Cell Biol. 12, 814-822.
109. Young, A. R., Narita, M., Ferreira, M., Kirschner, K., Sadaie, M., Darot, J. F., et al. (2009). Autophagy mediates the mitotic senescence transition. Genes Dev. 23, 798-803.
110. Zhang, H. H., Lipovsky, A. I., Dibble, C. C., Sahin, M., and Manning, B. D. (2006). S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol. Cell 24, 185-197.
111. Zhang, J., Gao, Z., Yin, J., Quon, M. J., and Ye, J. (2008). S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2. J. Biol. Chem. 283, 35375-35382.
112. Zhang, S., Tang, Q., Xu, F., Xue, Y., Zhen, Z., Deng, Y., et al. (2009). RhoA regulates G1-S progression of gastric cancer cells by modulation of multiple INK4 family tumor suppressors. Mol. Cancer Res. 7, 570-580.